Eton Pharmaceuticals, Inc. (ETON): M&A transaction — Eton Pharma closes $22.5M Increlex acquisition; expands credit facility

Eton Pharmaceuticals, Inc.

Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.
Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.
Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.
U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.
Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. for $22.5 million at closing, plus an additional $8.7 million for product inventory (closed 2024-12-19).

Action: acquisition
Counterparty: Ipsen S.A.
Consideration: $22.5 million at closing, plus an additional $8.7 million for product inventory
Closing: 2024-12-19

Exact text from the filing

to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). Under the terms of the purchase agreement, the Company acquired Increlex® for $22.5 million at closing, plus an additional $8.7 million for product inventory. The Company will also make payments to seller of $2.5 million on each of the first and second anniversaries of

View on SEC.gov

Browse all m&a transactions →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-038020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.